The collaboration between IGX Bio and CBIS is intended to help provide new insights into the role of inflammation and therapeutic vaccination of HIV as a critical step for optimizing effective treatments for AIDS patients in various resource settings. These studies will provide a scientific evaluation of GenePro® and CS-TATI-1 to demonstrate the enhanced potential of therapeutic vaccination and the anti-inflammatory effects of cannabinoids to deter disease progression in AIDS patients unable to achieve control HIV replication," stated Mr. Raymond C. Dabney, Cannabis Science, Inc., President & CEO, Co-Founder.
About IGXBio
IGXBio is a privately held clinical stage biotechnology company developing advanced DNA immunotherapies for HIV infection, based in Fairway, KS, USA.
